Publication: L1 Retrotransposon Heterogeneity in Ovarian Tumor Cell Evolution.
No Thumbnail Available
Identifiers
Date
2018
Authors
Nguyen, Thu H M
Carreira, Patricia E
Sanchez-Luque, Francisco J
Schauer, Stephanie N
Fagg, Allister C
Richardson, Sandra R
Davies, Claire M
Jesuadian, J Samuel
Kempen, Marie-Jeanne H C
Troskie, Robin-Lee
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
LINE-1 (L1) retrotransposons are a source of insertional mutagenesis in tumor cells. However, the clinical significance of L1 mobilization during tumorigenesis remains unclear. Here, we applied retrotransposon capture sequencing (RC-seq) to multiple single-cell clones isolated from five ovarian cancer cell lines and HeLa cells and detected endogenous L1 retrotransposition in vitro. We then applied RC-seq to ovarian tumor and matched blood samples from 19 patients and identified 88 tumor-specific L1 insertions. In one tumor, an intronic de novo L1 insertion supplied a novel cis-enhancer to the putative chemoresistance gene STC1. Notably, the tumor subclone carrying the STC1 L1 mutation increased in prevalence after chemotherapy, further increasing STC1 expression. We also identified hypomethylated donor L1s responsible for new L1 insertions in tumors and cultivated cancer cells. These congruent in vitro and in vivo results highlight L1 insertional mutagenesis as a common component of ovarian tumorigenesis and cancer genome heterogeneity.
Description
MeSH Terms
Antineoplastic Agents
Cell Line, Tumor
DNA Methylation
Drug Resistance, Neoplasm
Evolution, Molecular
Female
Gene Expression Regulation, Neoplastic
Glycoproteins
Humans
Long Interspersed Nucleotide Elements
Loss of Heterozygosity
Mutagenesis, Insertional
Mutation
Ovarian Neoplasms
Cell Line, Tumor
DNA Methylation
Drug Resistance, Neoplasm
Evolution, Molecular
Female
Gene Expression Regulation, Neoplastic
Glycoproteins
Humans
Long Interspersed Nucleotide Elements
Loss of Heterozygosity
Mutagenesis, Insertional
Mutation
Ovarian Neoplasms
DeCS Terms
CIE Terms
Keywords
L1, LINE-1, chemoresistance, ovarian cancer, retrotransposon